This company listing is no longer active
このページの翻訳は実験的なもので、現在 開発中です。お待ちしております!
Albireo Pharma 配当金
配当金 基準チェック /06
主要情報
n/a
配当利回り
n/a
配当性向
業界平均利回り | 2.8% |
次回配当支払日 | n/a |
配当落ち日 | n/a |
一株当たり配当金 | n/a |
一株当たり利益 | -US$6.29 |
3年後の配当利回り予想 | n/a |
最近の配当金アップデート
更新なし
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13決済の安定と成長
配当データの取得
安定した配当: Insufficient data to determine if ALBO's dividends per share have been stable in the past.
増加する配当: Insufficient data to determine if ALBO's dividend payments have been increasing.
配当利回り対市場
Albireo Pharma 配当利回り対市場 |
---|
セグメント | 配当利回り |
---|---|
会社 (ALBO) | n/a |
市場下位25% (US) | 1.5% |
市場トップ25% (US) | 4.7% |
業界平均 (Biotechs) | 2.8% |
3年後のアナリスト予想 (ALBO) | n/a |
注目すべき配当: Unable to evaluate ALBO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
高配当: Unable to evaluate ALBO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
株主への利益配当
収益カバレッジ: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
株主配当金
キャッシュフローカバレッジ: Unable to calculate sustainability of dividends as ALBO has not reported any payouts.